Scientists and entrepreneurs have tried for years to develop a safe and universal blood substitute that did not spoil after 42 days. However, all such efforts have encountered serious safety problems.
AHRP is concerned about the ethics and safety of human subjects in a blood storage experiment ( RECESS) sponsored
by the National Heart Lung and Blood Institute.
Dr. Marcia Angell, a senior lecturer at Harvard Medical School, and former editor of the New England Journal of Medicine and author of The Truth About Drug Companies, describes Sharav as an extraordinarily observant and valuable critic. "I see her as someone the research establishment badly needs."
American medicine is fast descending into lethal medicine thanks to FDA officials who lend the government seal of approval to drugs and experiments that kill.
Below the New York Times provides a summary of Crawford's selective disclosure and concealment of his financial holdings while he was
Commissioner, noting Crawford's ignoble tenure:
Tomorrow Hearing FDA’s Emergency Research Rule–CNN News at 8:00 P.M will inform the public about how the FDA Rule impacts on American citizens who can be put at increased risk to test an experimental treatment without their knowledge or consent.
The Phase I trial–the first in humans–was set up by US drug research company Parexel International Corp on behalf of German pharmaceutical company TeGenero.
In a blistering letter addressed to the Secretary of Health and Human Services, Senator Grassley calls upon Michael Leavitt to give “immediate attention” to the serious issues raised by a Northfield Laboratory, non-consensual artificial blood experiment.
Did OHRP conduct an investigation of the PolyHeme blood experiment and did OHRP issue a report of its findings?
This controversial, commercial experiment is being conducted without informed consent in trauma patients who require blood to survive. PolyHeme is being tested in patients in ambulances and at hospital emergency facilities where these trauma patients are denied life-saving real blood.
The Wall Street Journal reports: “The FDA is allowing Northfield [Laboratories, Inc] to test its blood substitute without the consent of the trauma patients, who often are unconscious.”
